INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.